China is surging in global pharma innovation. One-third of the world's innovative drugs in development come from China, including star anti-cancer treatments like Zanubrutinib and Ivonescimab. In 2025, overseas licensing deals for Chinese innovative drugs soared past US$130 billion, a historic high for the sector, according to a Wednesday briefing.